SNSS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SNSS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Sunesis Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-21.44 Mil, and Market Cap is $96.34 Mil. Therefore, Sunesis Pharmaceuticals's FCF Yield % for today is 0.00%.
The historical rank and industry rank for Sunesis Pharmaceuticals's FCF Yield % or its related term are showing as below:
Sunesis Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2020 was 0.00%.
The historical data trend for Sunesis Pharmaceuticals's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunesis Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial | -13.94 | -8.17 | -44.76 | -16.85 | -17.00 |
Sunesis Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | |
FCF Yield % | Get a 7-Day Free Trial | -11.39 | -14.20 | -22.55 | -21.42 | -17.96 |
For the Biotechnology subindustry, Sunesis Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Sunesis Pharmaceuticals's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Sunesis Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2020 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -21.439 | / | 126.124490583 | |
= | -17.00% |
Sunesis Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2020 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -5.663 | * | 4 | / | 126.124490583 | |
= | -17.96% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunesis Pharmaceuticals FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Steve Carchedi | director | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Nicole Onetto | director | 58 S SERVICE RD, MELVILLE NY 11747 |
Henry Ward Wolff | director | 6701 KAISER DRIVE, FREMONT CA 94555 |
Steven B Ketchum | director | 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303 |
James W Young | director | |
Homer L Pearce | director | 84 CLIFDEN, ZIONSVILLE IN 46077 |
Dayton Misfeldt | director, officer: See Remarks | C/O BAY CITY CAPITAL LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111 |
David C Stump | director | |
Tina Gullotta | officer: VP, Finance | SUNESIS PHARMACEUTICALS,INC, 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
William P. Quinn | officer: See Remarks | SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
Judith A. Fox | officer: See Remarks | SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
Aisling Capital Iv, Lp | 10 percent owner | 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
Andrew N Schiff | 10 percent owner | PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
Steve Elms | 10 percent owner | 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106 |
Aisling Capital Partners Iv Llc | 10 percent owner | 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
From GuruFocus
By Business Wire Business Wire • 12-30-2020
By Business Wire Business Wire • 12-04-2020
By Marketwired Marketwired • 12-05-2019
By Marketwired Marketwired • 01-08-2021
By Marketwired Marketwired • 10-12-2020
By Marketwired Marketwired • 05-08-2020
By PRNewswire PRNewswire • 12-01-2020
By PRNewswire PRNewswire • 02-25-2021
By PRNewswire PRNewswire • 12-05-2020
By PRNewswire PRNewswire • 12-07-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.